secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-05-14T12:01:38+00:00
Accession:  0001664710-26-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis
--------------------------------------------------------------------------------

- Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.
- R&D expenses fell 67% to $16.1M from $48.7M; transition of elritercept to Takeda and restructuring.
- Cash $281.5M as of Mar 31, 2026; expected funding into first half 2028.
- Takeda plans Phase 3 trial of elritercept for anemia in myelofibrosis, broadening beyond MDS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/0001664710-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/kros-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer